NG12 has no recommendation specific to haematospermia, so the safety step borrows the adjacent NG12 criteria: a prostate that feels malignant is a direct referral, a PSA above the age-specific range (when tested for an appropriate indication) is a referral, and visible haematuria has its own bladder-cancer route. Beyond that, risk is stratified by age, persistence and associated haematuria — the approach taken in the international EAU guidelines on sexual and reproductive health (haemospermia section), which advise PSA and DRE in counselled men over 40. The absolute cancer risk is small but real: in a US screening cohort, 13.7% of men reporting haematospermia were diagnosed with prostate cancer versus 6.5% overall (Han et al, J Urol 2004), and a UK tertiary series of 393 men investigated for haematospermia found prostate cancer in 5.3% overall and 7.2% of those aged 40 or over (Current Urology 2022). Fever with perineal pain needs same-day assessment because acute bacterial prostatitis can progress to sepsis or retention.

History does most of the risk stratification. Recent prostate biopsy or other instrumentation explains a large share of cases and needs no work-up beyond reassurance, while a young man with a single episode, no other symptoms and a normal examination is managed with explanation and review. Age over 40 with persistence or recurrence, urinary symptoms, haematuria, or a strong family history moves him towards PSA, DRE and a lower threshold for urology. Checking that the blood is truly from the ejaculate (not the partner, not the urine) prevents both false reassurance and needless investigation. Exploring the man's own fear — usually cancer, sometimes infection or fertility — shapes an explanation that he will actually accept.

Classification drives investigation and management. Idiopathic haematospermia (most common in young men) needs minimal work-up, and iatrogenic bleeding after biopsy is expected and self-limiting. Infective causes need targeted microbiological tests and, for STIs, partner management. Structural causes such as seminal vesicle or ejaculatory duct cysts are found on specialist imaging and are the usual explanation for persistent haematospermia in otherwise well younger men. The key decision in primary care is not to find the exact cause but to separate the benign, self-limiting group from the higher-risk group that needs PSA, DRE and urology.

Examination is where the NG12 criteria are triggered or excluded. A prostate that feels malignant on DRE is a suspected cancer pathway referral in its own right under NICE NG12 (updated April 2026), regardless of the PSA value, so offer DRE whenever prostate disease is a concern. Testicular examination can reveal a painless mass, which carries its own NG12 route. A tender prostate with fever points to acute bacterial prostatitis, where the examination should be gentle and the priority is antibiotics and a sepsis assessment. In the SCA, explaining why an intimate examination is needed, offering a chaperone and seeking consent are marked just as much as the findings.

NICE NG12 (updated April 2026) sets age-specific PSA thresholds for referral: above 2.5 ng/mL at 40–49, 3.5 at 50–59, 4.5 at 60–69 and 6.5 at 70–79, with clinical judgement outside those ages. Government PSA-testing guidance for GPs advises avoiding ejaculation and vigorous exercise in the 48 hours before a test and avoiding testing within 6 weeks of a prostate biopsy or cystoscopy, because each can raise PSA; prostatitis and UTI raise it too, so a result taken during infection should be repeated after treatment. Blood tests for coagulation are targeted, not routine. Specialist imaging (transrectal ultrasound, MRI) belongs to urology, where it is used for persistent haematospermia and for older men. In the young man with a single episode and a normal assessment, extra tests add anxiety without benefit.

NICE NG12 (updated April 2026) directs a suspected cancer pathway referral when the prostate feels malignant or the PSA is above the age-specific range, and has separate routes for visible haematuria and testicular change. Haematospermia alone in an older man with a normal PSA and DRE does not meet an NG12 criterion, but persistence or recurrence still warrants clinical review and, if unexplained or troublesome, the local urology pathway — the EAU guidance (international) stratifies these men as higher risk and uses MRI and transrectal ultrasound to look for structural causes and cancer. Since October 2023, NG12's suspected cancer pathway is aligned to the Faster Diagnosis Standard (diagnosis or exclusion within 28 days). The GP's role is risk stratification, correct routing and safety-netting, not definitive investigation of complex haematospermia.

Reassurance is the most powerful intervention for idiopathic haematospermia — anxiety about the symptom often exceeds clinical risk. Antibiotics are only for a demonstrated or strongly suspected infection. For acute bacterial prostatitis, NICE NG110 recommends a 14-day course then review, with the antibiotic guided by culture, previous exposure, local resistance, severity and renal function; since January 2024 the MHRA has restricted systemic fluoroquinolones to situations where other recommended antibiotics are inappropriate, because of disabling and potentially long-lasting adverse effects. Confirmed chlamydia is treated with doxycycline 100 mg twice daily for 7 days per BASHH, with partner notification. Blood pressure and anticoagulation are optimised, not simply stopped.

Anxiety about haematospermia is often disproportionate to clinical risk, and clear, confident reassurance with a concrete plan reduces re-attendance and repeated testing. Specific advice lands better than general statements: what is expected after a biopsy, when sex is fine, what the partner needs to know. STI prevention matters because infection is a treatable cause in younger, sexually active men. Blood pressure control and alcohol moderation address the vascular and bleeding contributors. The prostate-awareness conversation follows the government's PSA-testing guidance for GPs, which supports informed choice rather than routine screening.

The review serves two functions: confirming resolution (the majority) and catching the minority where pathology is emerging. A PSA taken during active prostatitis or UTI is unreliable and should be repeated once the infection has settled rather than acted on in isolation. Safety-netting for retention and sepsis is critical because acute prostatitis can escalate quickly, and new visible haematuria converts the problem into an NG12 bladder pathway. In the SCA, the examiner is looking for the balance between reassurance and appropriate testing: acknowledging the man's fear, explaining why age changes the approach, offering DRE and PSA with consent, and giving specific return advice.